WO1998019698A1 - Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity - Google Patents
Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity Download PDFInfo
- Publication number
- WO1998019698A1 WO1998019698A1 PCT/US1997/020114 US9720114W WO9819698A1 WO 1998019698 A1 WO1998019698 A1 WO 1998019698A1 US 9720114 W US9720114 W US 9720114W WO 9819698 A1 WO9819698 A1 WO 9819698A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glp
- composition
- peptide
- analogs
- pharmaceutically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA99063107A UA65549C2 (en) | 1996-11-05 | 1997-04-11 | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
AT97947357T ATE234112T1 (en) | 1996-11-05 | 1997-11-04 | PERIPHERAL ADMINISTRATION OF GLP-1 ANALOGUES AND DERIVATIVES FOR REGULATION OF OBESITY |
IL129852A IL129852A (en) | 1996-11-05 | 1997-11-04 | Use of an agonist of the glp-1 receptor in the manufacture of a medicament for the reduction of body weight |
EP97947357A EP0946191B1 (en) | 1996-11-05 | 1997-11-04 | Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity |
AU52457/98A AU734042B2 (en) | 1996-11-05 | 1997-11-04 | Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity |
DE69719798T DE69719798T2 (en) | 1996-11-05 | 1997-11-04 | PERIPHERAL ADMINISTRATION OF GLP-1 ANALOGS AND DERIVATIVES FOR REGULATING OBESITY |
PL334317A PL191627B1 (en) | 1996-11-05 | 1997-11-04 | Application of peripherally administered glp-1 analoques and derivatives in treating obesity |
DK97947357T DK0946191T3 (en) | 1996-11-05 | 1997-11-04 | Use of GLP-1 analogs and derivatives administered peripherally for the control of obesity |
CNB971812322A CN1268391C (en) | 1996-11-05 | 1997-11-04 | Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity |
CA2271169A CA2271169C (en) | 1996-11-05 | 1997-11-04 | Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity |
NZ335995A NZ335995A (en) | 1996-11-05 | 1997-11-04 | Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity |
NO992557A NO992557L (en) | 1996-11-05 | 1999-05-27 | Use of GLP-1 analogues and derivatives administered peripherally in the control of obesity |
HK00104161A HK1024874A1 (en) | 1996-11-05 | 2000-07-06 | Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3021396P | 1996-11-05 | 1996-11-05 | |
US60/030,213 | 1996-11-05 | ||
US08/961,405 | 1997-10-30 | ||
US08/961,405 US6191102B1 (en) | 1996-11-05 | 1997-10-30 | Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998019698A1 true WO1998019698A1 (en) | 1998-05-14 |
Family
ID=26705788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/020114 WO1998019698A1 (en) | 1996-11-05 | 1997-11-04 | Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity |
Country Status (19)
Country | Link |
---|---|
US (4) | US6191102B1 (en) |
EP (1) | EP0946191B1 (en) |
CN (1) | CN1268391C (en) |
AT (1) | ATE234112T1 (en) |
AU (1) | AU734042B2 (en) |
CA (1) | CA2271169C (en) |
DE (1) | DE69719798T2 (en) |
DK (1) | DK0946191T3 (en) |
ES (1) | ES2194224T3 (en) |
HK (1) | HK1024874A1 (en) |
HU (1) | HUP0003314A3 (en) |
IL (1) | IL129852A (en) |
MY (1) | MY129220A (en) |
NO (1) | NO992557L (en) |
NZ (1) | NZ335995A (en) |
PT (1) | PT946191E (en) |
UA (1) | UA65549C2 (en) |
WO (1) | WO1998019698A1 (en) |
YU (1) | YU24199A (en) |
Cited By (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999047161A1 (en) * | 1998-03-19 | 1999-09-23 | Bionebraska, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
EP0997151A2 (en) * | 1998-08-28 | 2000-05-03 | Eli Lilly And Company | Method for administering insulinotropic peptides |
WO2000034331A2 (en) * | 1998-12-07 | 2000-06-15 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Analogues of glp-1 |
US6162907A (en) * | 1986-05-05 | 2000-12-19 | The General Hospital Corporation | DNA encoding insulinotropic hormone |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
WO2001087322A2 (en) * | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
WO2001098331A2 (en) * | 2000-06-16 | 2001-12-27 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
EP1359159A3 (en) * | 1998-12-07 | 2004-07-21 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Analogues of GLP-1 |
US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
EP0941114B1 (en) * | 1996-11-12 | 2005-02-23 | Novo Nordisk A/S | Use of glp-1 peptides |
US6956026B2 (en) | 1997-01-07 | 2005-10-18 | Amylin Pharmaceuticals, Inc. | Use of exendins for the reduction of food intake |
WO2005120492A1 (en) * | 2004-06-11 | 2005-12-22 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
US6998387B1 (en) | 1998-03-19 | 2006-02-14 | Amylin Pharmaceuticals, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
EP1666054A1 (en) * | 1998-08-28 | 2006-06-07 | Eli Lilly & Company | Method for administering insulinotropic peptides |
US7101843B2 (en) * | 2001-08-23 | 2006-09-05 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
EP1709071A1 (en) * | 2004-01-08 | 2006-10-11 | Theratechnologies Inc. | Glucagon-like peptide-1 analogs with long duration of action |
US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US7223725B1 (en) | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
AU785444B2 (en) * | 2000-05-19 | 2007-06-14 | Jefferson Pharmaceuticals, Llc | Peptide pharmaceutical formulations |
US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US7238660B2 (en) | 2001-12-21 | 2007-07-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7368427B1 (en) | 1998-12-07 | 2008-05-06 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | GLP-1 analogues |
EP2015769A2 (en) * | 2006-04-13 | 2009-01-21 | Societe de Conseils de Recherches et d'Applications Scientifique | Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof |
WO2009020802A2 (en) * | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
US7521527B2 (en) | 2003-12-16 | 2009-04-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | GLP-1 pharmaceutical compositions |
EP2062593A2 (en) | 2000-12-01 | 2009-05-27 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive peptide |
US7544657B2 (en) | 2002-10-02 | 2009-06-09 | Zealand Pharma A/S | Stabilized Exendin-4 compounds |
EP2112161A2 (en) | 1999-07-12 | 2009-10-28 | Zealand Pharma A/S | Peptides that lower blood glucose levels |
WO2009153960A1 (en) | 2008-06-17 | 2009-12-23 | 大塚化学株式会社 | Glycosylated glp-1 peptide |
US7696161B2 (en) | 1997-11-14 | 2010-04-13 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
EP2216042A1 (en) | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP-1 analogues pharmaceutical compositions |
US7799759B2 (en) | 2001-12-21 | 2010-09-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2010129248A1 (en) | 2009-05-06 | 2010-11-11 | Centocor Ortho Biotech Inc. | Melanocortin receptor binding conjugates |
US7897566B2 (en) | 2003-12-16 | 2011-03-01 | Ipsen Pharma S.A.S. | Analogues of GLP-1 |
WO2011052523A1 (en) | 2009-10-30 | 2011-05-05 | 大塚化学株式会社 | Glycosylated form of antigenic glp-1 analogue |
US7939494B2 (en) | 2002-02-20 | 2011-05-10 | Emisphere Technologies, Inc. | Method for administering GLP-1 molecules |
EP2343082A1 (en) * | 2001-09-07 | 2011-07-13 | Imperial Innovations Limited | Oxyntomodulin for preventing or treating excess weight |
WO2011089203A1 (en) * | 2010-01-21 | 2011-07-28 | Sanofi-Aventis | Pharmaceutical composition for treating a metabolic syndrome |
EP2368909A1 (en) | 2003-06-12 | 2011-09-28 | Eli Lilly and Company | GLP-1 analog fusion proteins |
EP2441460A1 (en) | 2005-06-30 | 2012-04-18 | Ipsen Pharma | GLP-1 pharmaceutical compositions |
US8183340B2 (en) | 2005-05-13 | 2012-05-22 | Eli Lilly And Company | GLP-1 pegylated compounds |
US8338368B2 (en) | 2005-11-07 | 2012-12-25 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
WO2013049234A2 (en) | 2011-09-26 | 2013-04-04 | Novartis Ag | Dual function proteins for treating metabolic disorders |
US8450270B2 (en) | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
WO2013093720A2 (en) | 2011-12-22 | 2013-06-27 | Pfizer Inc. | Anti-diabetic compounds |
US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US8546327B2 (en) | 2008-06-17 | 2013-10-01 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
US8614185B2 (en) | 2009-05-04 | 2013-12-24 | Centocor Ortho Biotech Inc. | Fusion proteins of alpha-MSH derivatives and Fc |
WO2014010586A1 (en) | 2012-07-10 | 2014-01-16 | 武田薬品工業株式会社 | Pharmaceutical preparation for injection |
US8669228B2 (en) | 2007-01-05 | 2014-03-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8778872B2 (en) | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
US8785381B2 (en) | 2003-12-19 | 2014-07-22 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
USRE45313E1 (en) | 1999-07-12 | 2014-12-30 | Zealand Pharma A/S | Exendin variant peptides |
WO2015021871A1 (en) | 2013-08-13 | 2015-02-19 | 杭州鸿运华宁生物医药工程有限公司 | Antibody specifically binding to glp-1r and fusion protein thereof with glp-1 |
US8969288B2 (en) | 2008-12-19 | 2015-03-03 | Indiana University Research And Technology Corporation | Amide based glucagon and superfamily peptide prodrugs |
US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
US8981047B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Glucagon antagonists |
WO2015057908A1 (en) | 2013-10-18 | 2015-04-23 | Novartis Ag | Methods of treating diabetes and related disorders |
US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
US9089538B2 (en) | 2010-04-27 | 2015-07-28 | Zealand Pharma A/S | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use |
WO2015124612A1 (en) * | 2014-02-18 | 2015-08-27 | Novo Nordisk A/S | Stable glucagon analogues and use for treatment of hypoglycaemia |
US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9200051B2 (en) | 2013-05-28 | 2015-12-01 | Takeda Pharmaceutical Company Limited | Peptide compound |
US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US9364519B2 (en) | 2011-09-01 | 2016-06-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
US9408893B2 (en) | 2011-08-29 | 2016-08-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
US9486504B2 (en) | 2003-12-09 | 2016-11-08 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
US9526764B2 (en) | 2008-10-17 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1-agonist |
US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US9839675B2 (en) | 2013-02-04 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US9861706B2 (en) | 2011-11-03 | 2018-01-09 | Zealand Pharma A/S | GLP-1 receptor agonist peptide gastrin conjugates |
US9895423B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
US9975939B2 (en) | 2012-09-17 | 2018-05-22 | Zealand Pharma A/S | Glucagon analogues |
US9981013B2 (en) | 2010-08-30 | 2018-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
US10029011B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
US10131702B2 (en) | 2013-11-06 | 2018-11-20 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
US10159713B2 (en) | 2015-03-18 | 2018-12-25 | Sanofi-Aventis Deutschland Gmbh | Treatment of type 2 diabetes mellitus patients |
US10253078B2 (en) | 2014-10-29 | 2019-04-09 | Zealand Pharma A/S | GIP agonist compounds and methods |
US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
WO2019170153A1 (en) | 2018-03-09 | 2019-09-12 | Shanghai Benemae Pharmaceutical Corporation | GLP-1 Composition for Treating Obesity and Weight Management |
US10413593B2 (en) | 2014-10-24 | 2019-09-17 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and GLP-1 receptors |
WO2019179424A1 (en) | 2018-03-20 | 2019-09-26 | 鸿运华宁(杭州)生物医药有限公司 | Gipr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof |
US10434147B2 (en) | 2015-03-13 | 2019-10-08 | Sanofi-Aventis Deutschland Gmbh | Treatment type 2 diabetes mellitus patients |
US10457714B2 (en) | 2013-10-17 | 2019-10-29 | Zealand Pharma A/S | Acylated glucagon analogues |
US10501516B2 (en) | 2016-05-24 | 2019-12-10 | Takeda Pharmaceutical Company Limited | Peptide compound |
US10538569B2 (en) | 2014-12-31 | 2020-01-21 | Genexine, Inc. | Fusion polypeptide containing GLP and immunoglobulin hybrid Fc and use thereof |
US10905745B2 (en) | 2016-12-09 | 2021-02-02 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
WO2021052349A1 (en) | 2019-09-18 | 2021-03-25 | 鸿运华宁(杭州)生物医药有限公司 | Gipr antibody and fusion protein between same and glp-1, and pharmaceutical composition and application thereof |
US11034747B2 (en) | 2013-10-17 | 2021-06-15 | Zealand Pharma A/S | Glucagon analogues and methods of use |
US11318191B2 (en) | 2020-02-18 | 2022-05-03 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
US11752198B2 (en) | 2017-08-24 | 2023-09-12 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
US11752173B2 (en) | 2017-12-19 | 2023-09-12 | Beijing Jiyuan Biological Technology Co., Ltd. | FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease |
US11795204B2 (en) | 2012-07-23 | 2023-10-24 | Zealand Pharma A/S | Glucagon analogues |
Families Citing this family (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (en) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
UA65549C2 (en) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
EP1012188B1 (en) * | 1997-09-12 | 2004-08-18 | Pharis Biotec GmbH | Composition for treating diabetes mellitus and obesity |
US6605648B1 (en) * | 1999-04-06 | 2003-08-12 | Phillips Plastics Corporation | Sinterable structures and method |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
ATE252601T1 (en) * | 1999-05-17 | 2003-11-15 | Conjuchem Inc | LONG-ACTING INSULINOTROPE PEPTIDES |
US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US6344180B1 (en) | 1999-06-15 | 2002-02-05 | Bionebraska, Inc. | GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
AU779986B2 (en) | 1999-06-29 | 2005-02-24 | Mannkind Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
US6569901B2 (en) * | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
EP1276849A4 (en) * | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusion proteins |
SI1724284T1 (en) * | 2000-12-07 | 2009-12-31 | Lilly Co Eli | GLP-1 fusion proteins |
MXPA03005135A (en) * | 2000-12-13 | 2003-12-04 | Lilly Co Eli | Chronic treatment regimen using glucagon-like insulinotropic peptides. |
US7803982B2 (en) | 2001-04-20 | 2010-09-28 | The Mount Sinai School Of Medicine Of New York University | T1R3 transgenic animals, cells and related methods |
US20040219632A1 (en) * | 2001-04-20 | 2004-11-04 | Robert Margolskee | T1r3 a novel taste receptor |
WO2002097038A2 (en) * | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
WO2003014318A2 (en) * | 2001-08-08 | 2003-02-20 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
US20040143104A1 (en) * | 2001-08-08 | 2004-07-22 | Wadsworth Samuel C. | Methods of treating diabetes and other blood sugar disorders |
WO2003020201A2 (en) * | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
EP2050460A1 (en) * | 2001-09-24 | 2009-04-22 | Imperial Innovations Limited | PYY and agonists thereof for modification of feeding behaviour |
US7179788B2 (en) * | 2001-10-19 | 2007-02-20 | Eli Lilly And Company | Biphasic mixtures of GLP-1 and insulin |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
JP4733922B2 (en) * | 2002-01-10 | 2011-07-27 | インペリアル・イノベ−ションズ・リミテッド | Correction of eating behavior |
DE60335608D1 (en) * | 2002-02-27 | 2011-02-17 | Pharmain Corp | COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
ES2300568T3 (en) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | INHALATION APPARATUS |
AU2003225277A1 (en) * | 2002-05-02 | 2003-11-17 | Robert Harris | Lipid removal from the body |
US7374930B2 (en) * | 2002-05-21 | 2008-05-20 | Expression Genetics, Inc. | GLP-1 gene delivery for the treatment of type 2 diabetes |
US7329798B2 (en) * | 2002-06-28 | 2008-02-12 | University Of Guelph | Harvest-inducible regulatory elements and methods of using same |
CA2490564A1 (en) * | 2002-07-04 | 2004-01-15 | Zealand Pharma A/S | Glp-1 and methods for treating diabetes |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
AU2003283004A1 (en) * | 2002-10-22 | 2004-05-13 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
US7229966B2 (en) * | 2002-12-17 | 2007-06-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
EA008829B1 (en) * | 2002-12-17 | 2007-08-31 | Нэстек Фармасьютикал Кампани Инк. | Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity |
US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
US7186692B2 (en) * | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
CN1771080B (en) * | 2003-04-08 | 2010-12-15 | 诺沃挪第克公司 | Method for producing therapeutic peptide or its precursor comprising at least one chromatographic step |
WO2004089985A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Stable pharmaceutical compositions |
ES2737835T3 (en) | 2003-04-23 | 2020-01-16 | Valeritas Inc | Hydraulically driven pump for long-term medication administration |
EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
ES2725808T3 (en) | 2003-05-23 | 2019-09-27 | Nektar Therapeutics | PEG derivatives containing two PEG chains |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20050244810A1 (en) * | 2003-09-29 | 2005-11-03 | Egan Josephine M | Taste signaling in gastrointestinal cells |
US20050107318A1 (en) * | 2003-11-17 | 2005-05-19 | Samuel Wadsworth | Methods of treating diabetes and other blood sugar disorders |
JP2007519642A (en) * | 2004-01-30 | 2007-07-19 | ワラタ ファーマシューティカルズ, インコーポレイテッド | Combined use of a GLP-1 agonist and gastrin to regulate blood glucose levels |
BRPI0507026A (en) * | 2004-02-09 | 2007-04-17 | Human Genome Sciences Inc | albumin fusion proteins |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005097175A2 (en) * | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
ES2347902T3 (en) * | 2004-04-23 | 2010-11-22 | Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 | SOLID PHASE FOR USE IN A PROCEDURE FOR PURIFICATION OF ALBUMINE CONJUGATES. |
WO2005118555A1 (en) * | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006014425A1 (en) * | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
MX2007001903A (en) | 2004-08-20 | 2007-08-02 | Mannkind Corp | Catalysis of diketopiperazine synthesis. |
KR101306384B1 (en) | 2004-08-23 | 2013-09-09 | 맨카인드 코포레이션 | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
EP1874339A1 (en) * | 2005-04-21 | 2008-01-09 | Gastrotech Pharma A/S | Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug |
RU2007149288A (en) * | 2005-05-27 | 2009-07-10 | Асубио Фарма Ко., Лтд. (Jp) | MEANS FOR REDUCING RESISTANCE TO INSULIN |
GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
US20070016262A1 (en) | 2005-07-13 | 2007-01-18 | Betastim, Ltd. | Gi and pancreatic device for treating obesity and diabetes |
US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
JP5465878B2 (en) | 2005-09-14 | 2014-04-09 | マンカインド コーポレイション | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US8039432B2 (en) * | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
US20070149442A1 (en) * | 2005-12-13 | 2007-06-28 | Byron Rubin | Non-hygroscopic compositions of enterostatin |
AU2006326502A1 (en) * | 2005-12-13 | 2007-06-21 | Harkness Pharmaceuticals, Inc. | Methods of treating obesity using enterostatin |
WO2007070563A2 (en) * | 2005-12-13 | 2007-06-21 | Harkness Pharmaceuticals, Inc. | Stable solid forms of enterostatin |
US8293869B2 (en) | 2005-12-16 | 2012-10-23 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
KR101872061B1 (en) | 2005-12-19 | 2018-06-27 | 파마인 코포레이션 | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
AU2006329215A1 (en) * | 2005-12-22 | 2007-06-28 | Conjuchem Biotechnologies Inc. | Process for the production of preformed conjugates of albumin and a therapeutic agent |
CN104383546B (en) | 2006-02-22 | 2021-03-02 | 曼金德公司 | Method for improving the pharmaceutical properties of microparticles comprising diketopiperazines and an active agent |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2009532117A (en) | 2006-03-30 | 2009-09-10 | ヴァレリタス,エルエルシー | Multi-cartridge fluid dispensing device |
PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
MX2008014024A (en) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Polymorphs. |
DE602007009377D1 (en) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM |
CN101563364B (en) * | 2006-06-23 | 2014-04-02 | 霍夫曼-拉罗奇有限公司 | Insulinotropic peptide synthesis |
JP2009542813A (en) * | 2006-07-11 | 2009-12-03 | ハルクネスス プハルマセウティカルス,インコーポレイテッド | How to treat obesity with satiety factor |
CN101511868B (en) * | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | Exendin fusion proteins |
KR101200728B1 (en) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | Osmotic delivery system and piston assemblies |
US7839952B2 (en) * | 2006-12-05 | 2010-11-23 | Provigent Ltd | Data rate coordination in protected variable-rate links |
TWI428346B (en) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
BRPI0808157A2 (en) * | 2007-02-02 | 2014-07-01 | Redpoint Bio Corp | USE OF TRPM5 INHIBITOR FOR REGULATING INSULIN AND GLP-1 RELEASE |
AU2008244523B2 (en) * | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
AU2008316636B2 (en) * | 2007-10-24 | 2014-02-06 | Mannkind Corporation | Delivery of active agents |
MX2010004510A (en) * | 2007-10-24 | 2010-07-02 | Mannkind Corp | Method of preventing adverse effects by glp-1. |
US20090186819A1 (en) * | 2007-12-11 | 2009-07-23 | Marieve Carrier | Formulation of insulinotropic peptide conjugates |
US20090176892A1 (en) | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
CN101983066B (en) * | 2008-01-30 | 2016-06-29 | 印第安那大学科技研究公司 | Insulin prodrug based on ester |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
PE20091730A1 (en) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | FORMULATIONS INVOLVING A DPP4 INHIBITOR |
CN104689432B (en) | 2008-06-13 | 2018-07-06 | 曼金德公司 | Diskus and the system for drug conveying |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
JP5479465B2 (en) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | Interactive device and method for profiling inhalation efforts in real time |
BRPI0916997A2 (en) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | DPP-4 INHIBITOR AND ITS USE |
TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
EP2340049B1 (en) | 2008-09-12 | 2015-11-11 | Novo Nordisk A/S | Method of acylating a peptide or protein |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
US8650937B2 (en) | 2008-09-19 | 2014-02-18 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
US8481485B2 (en) | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
PL2405963T3 (en) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Apparatus, system and method for measuring resistance of an inhaler |
US8414559B2 (en) * | 2009-05-07 | 2013-04-09 | Rainbow Medical Ltd. | Gastroretentive duodenal pill |
US20110066175A1 (en) * | 2009-05-07 | 2011-03-17 | Rainbow Medical Ltd. | Gastric anchor |
US20100286628A1 (en) * | 2009-05-07 | 2010-11-11 | Rainbow Medical Ltd | Gastric anchor |
EP2440184B1 (en) | 2009-06-12 | 2023-04-05 | MannKind Corporation | Diketopiperazine microparticles with defined specific surface areas |
EP2724739B1 (en) | 2009-07-30 | 2015-07-01 | Tandem Diabetes Care, Inc. | Portable infusion pump system |
WO2011028455A1 (en) | 2009-09-02 | 2011-03-10 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
SI2462246T1 (en) | 2009-09-28 | 2018-01-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
JP5892940B2 (en) | 2009-11-25 | 2016-03-23 | アリスジェン ソシエテ アノニム | Mucosal delivery composition comprising a peptide complexed with a crown compound and / or counterion |
EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
WO2011103256A1 (en) | 2010-02-22 | 2011-08-25 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
WO2011123943A1 (en) | 2010-04-09 | 2011-10-13 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist |
AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
EP2571876B1 (en) | 2010-05-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
CN103068842B (en) | 2010-06-16 | 2016-10-19 | 印第安纳大学研究及科技有限公司 | Insulin receptor INSR is had highly active single-chain insulin agonist |
RU2571331C1 (en) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Systems and methods for dry powder drug delivery |
AP2013006671A0 (en) * | 2010-06-24 | 2013-01-31 | Zealand Pharma As | Glucagon analogues |
EP2585102B1 (en) | 2010-06-24 | 2015-05-06 | Indiana University Research and Technology Corporation | Amide-based insulin prodrugs |
EP2588490B1 (en) | 2010-07-02 | 2017-02-22 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
CN102643339B (en) * | 2011-02-21 | 2014-04-09 | 天津药物研究院 | GLP-1 analogs, preparation method thereof application thereof |
DK2694402T3 (en) | 2011-04-01 | 2017-07-03 | Mannkind Corp | BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
WO2013003449A2 (en) * | 2011-06-27 | 2013-01-03 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
CN104039344A (en) * | 2011-10-28 | 2014-09-10 | 法瑞斯生物技术有限公司 | A polypeptide for the protection against heart ischemia-reperfusion injury |
US20140336118A1 (en) * | 2011-10-28 | 2014-11-13 | Pharis Biotec Gmbh | Polypeptide for the protection against heart ischemia-reperfusion injury |
CN104114183A (en) | 2011-12-20 | 2014-10-22 | 印第安纳大学研究及科技有限公司 | CTP-based insulin analogs for treatment of diabetes |
US20130172244A1 (en) * | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013155600A1 (en) | 2012-04-16 | 2013-10-24 | Kaneq Pharma | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
JP6387008B2 (en) | 2012-09-26 | 2018-09-05 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Insulin analog dimer |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
WO2014158900A1 (en) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
EP3587404B1 (en) | 2013-03-15 | 2022-07-13 | MannKind Corporation | Microcrystalline diketopiperazine compositions, methods for preparation and use thereof |
CN103344764B (en) * | 2013-06-19 | 2014-11-26 | 天津美德太平洋科技有限公司 | Reagent, method and kit for detection of biological activity of glucagon-like peptide-1 (GLP-1) |
BR112016000937A8 (en) | 2013-07-18 | 2021-06-22 | Mannkind Corp | dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation |
JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
WO2015070050A1 (en) | 2013-11-08 | 2015-05-14 | Baylor Research Institute | Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure |
US9339482B2 (en) | 2013-11-22 | 2016-05-17 | Regents Of The University Of Minnesota | Methods to treat dysregulated blood glucose disorders |
ES2950384T3 (en) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Medical use of a DPP-4 inhibitor |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
EP3129467B1 (en) * | 2014-04-11 | 2019-11-13 | Université Catholique de Louvain | Transgenic pig islets and uses thereof for treating diabetes |
CN108271356A (en) | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | Duodenin-insulin conjugate |
JP6701208B2 (en) | 2014-09-24 | 2020-05-27 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | Lipidated amide insulin prodrug |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US11419543B1 (en) | 2016-03-03 | 2022-08-23 | Gholam A. Peyman | Early disease detection and therapy |
PL3257524T3 (en) | 2015-02-11 | 2021-03-08 | Gmax Biopharm Llc | Stabilized solution preparation of pharmaceutical glp-1r antibody fusion protein |
KR20240042548A (en) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | Implant placement and removal systems |
US11433260B2 (en) | 2015-12-21 | 2022-09-06 | Gholam A. Peyman | Cancer treatment methods using thermotherapy and/or enhanced immunotherapy |
US9849092B2 (en) | 2015-12-21 | 2017-12-26 | Gholam A. Peyman | Early cancer detection and enhanced immunotherapy |
US10136820B2 (en) | 2015-12-21 | 2018-11-27 | Gholam A. Peyman | Method to visualize very early stage neoplasm or other lesions |
US11090385B2 (en) | 2015-12-21 | 2021-08-17 | Gholam A. Peyman | Early cancer detection and enhanced immunotherapy |
US10300121B2 (en) | 2015-12-21 | 2019-05-28 | Gholam A. Peyman | Early cancer detection and enhanced immunotherapy |
US11660229B2 (en) | 2015-12-21 | 2023-05-30 | Gholam A. Peyman | Cancer treatment methods using thermotherapy and/or enhanced immunotherapy |
US10376600B2 (en) | 2016-03-03 | 2019-08-13 | Gholam A. Peyman | Early disease detection and therapy |
MA53353A (en) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
BR112018072401A2 (en) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinations of linagliptin and metformin |
CN107266556A (en) * | 2016-12-14 | 2017-10-20 | 江苏师范大学 | A kind of Africa xenopus glucagon-like peptide 1(GLP‑1)Analog and its application |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
MX2021004185A (en) | 2018-10-11 | 2021-09-08 | Intarcia Therapeutics Inc | Human amylin analog polypeptides and methods of use. |
GB201917723D0 (en) | 2019-12-04 | 2020-01-15 | Nv Rose Llc | Stable liquid formulations of glucagon-like peptide 1 or analogues thereof |
CN116925237A (en) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Fusion proteins of GLP-1 and GDF15 and conjugates thereof |
CN115322794A (en) | 2020-01-11 | 2022-11-11 | 北京质肽生物医药科技有限公司 | Conjugates of fusion proteins of GLP-1 and FGF21 |
CN115925994B (en) | 2020-09-30 | 2023-09-22 | 北京质肽生物医药科技有限公司 | Polypeptide conjugates and methods of use |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK179286D0 (en) * | 1986-04-18 | 1986-04-18 | Nordisk Gentofte | INSULIN PREPARATION |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
JP3262329B2 (en) | 1990-01-24 | 2002-03-04 | アイ. バックレイ,ダグラス | GLP-1 analog useful for the treatment of diabetes |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
JPH07505865A (en) | 1992-02-07 | 1995-06-29 | メレルダウファーマスーティカルズ インコーポレイテッド | Phenylalanine analogs of bombesin |
DK36392D0 (en) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | USE OF CHEMICAL COMPOUND |
PL176007B1 (en) | 1992-06-15 | 1999-03-31 | Scios Inc | Novel derivatives of polypeptide glp-1 |
WO1995005848A1 (en) | 1993-08-24 | 1995-03-02 | Novo Nordisk A/S | Protracted glp-1 |
CA2137206A1 (en) | 1993-12-09 | 1995-06-10 | John A. Galloway | Glucagon-like insulinotropic peptides, compositions and methods |
GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5693609A (en) * | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
GB9502830D0 (en) | 1995-02-14 | 1995-04-05 | Ecole Polytech | Regulation of polypeptide production in cells |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
PT1975177E (en) | 1996-03-01 | 2011-07-26 | Novo Nordisk As | An appetite-suppressing peptide, its compositions and use |
JP2001501593A (en) | 1996-08-08 | 2001-02-06 | アミリン・ファーマシューティカルズ,インコーポレイテッド | Methods for regulating gastrointestinal motility |
US5762953A (en) * | 1996-08-22 | 1998-06-09 | Theratech, Inc. | Transdermal propentofylline compositions for the treatment of Alzheimers disease |
UA72181C2 (en) | 1996-08-30 | 2005-02-15 | Ново Нордіск А/С | Derivatives of glucanolike peptide-1 |
EP0929576A1 (en) | 1996-08-30 | 1999-07-21 | Novo Nordisk A/S | Glp-2 derivatives |
UA65549C2 (en) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
DE69732572T2 (en) | 1996-11-12 | 2005-12-29 | Novo Nordisk A/S | USE OF GLP-1 PEPTIDES |
-
1997
- 1997-04-11 UA UA99063107A patent/UA65549C2/en unknown
- 1997-10-30 US US08/961,405 patent/US6191102B1/en not_active Expired - Lifetime
- 1997-11-04 DE DE69719798T patent/DE69719798T2/en not_active Revoked
- 1997-11-04 DK DK97947357T patent/DK0946191T3/en active
- 1997-11-04 CN CNB971812322A patent/CN1268391C/en not_active Expired - Lifetime
- 1997-11-04 PT PT97947357T patent/PT946191E/en unknown
- 1997-11-04 CA CA2271169A patent/CA2271169C/en not_active Expired - Lifetime
- 1997-11-04 ES ES97947357T patent/ES2194224T3/en not_active Expired - Lifetime
- 1997-11-04 EP EP97947357A patent/EP0946191B1/en not_active Revoked
- 1997-11-04 YU YU24199A patent/YU24199A/en unknown
- 1997-11-04 HU HU0003314A patent/HUP0003314A3/en unknown
- 1997-11-04 MY MYPI97005206A patent/MY129220A/en unknown
- 1997-11-04 IL IL129852A patent/IL129852A/en not_active IP Right Cessation
- 1997-11-04 AT AT97947357T patent/ATE234112T1/en not_active IP Right Cessation
- 1997-11-04 WO PCT/US1997/020114 patent/WO1998019698A1/en not_active Application Discontinuation
- 1997-11-04 NZ NZ335995A patent/NZ335995A/en not_active IP Right Cessation
- 1997-11-04 AU AU52457/98A patent/AU734042B2/en not_active Expired
-
1999
- 1999-05-27 NO NO992557A patent/NO992557L/en not_active Application Discontinuation
-
2000
- 2000-06-01 US US09/585,186 patent/US6583111B1/en not_active Expired - Lifetime
- 2000-07-06 HK HK00104161A patent/HK1024874A1/en not_active IP Right Cessation
-
2003
- 2003-05-05 US US10/429,522 patent/US7211557B2/en not_active Expired - Fee Related
-
2007
- 2007-03-30 US US11/693,877 patent/US20070173452A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
TURTON M D ET AL: "A role for glucagon-like peptide-1 in the central regulation of feeding", NATURE, vol. 379, 4 January 1996 (1996-01-04), ENGLAND, U.K., pages 69 - 72, XP002058608 * |
Cited By (205)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6162907A (en) * | 1986-05-05 | 2000-12-19 | The General Hospital Corporation | DNA encoding insulinotropic hormone |
US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
US7569540B2 (en) | 1995-08-22 | 2009-08-04 | Amylin Pharmaceuticals, Inc. | Method for enhanced parenteral nutrition |
US7741269B2 (en) | 1996-08-08 | 2010-06-22 | Amylin Pharmaceuticals, Inc. | Exendins and exendin agonists for weight reduction and obesity |
US7297761B2 (en) | 1996-08-08 | 2007-11-20 | Amylin Pharmaceuticals, Inc. | Pharmaceutical compositions containing exendins |
US8288338B2 (en) | 1996-08-08 | 2012-10-16 | Amylin Pharmaceuticals, Llc | Exendin and exendin agonists for eating disorders |
US8097698B2 (en) | 1996-08-30 | 2012-01-17 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
EP1529534A3 (en) * | 1996-11-12 | 2005-06-08 | Novo Nordisk A/S | Use of GLP-1 peptides |
EP1529534A2 (en) * | 1996-11-12 | 2005-05-11 | Novo Nordisk A/S | Use of GLP-1 peptides |
EP0941114B1 (en) * | 1996-11-12 | 2005-02-23 | Novo Nordisk A/S | Use of glp-1 peptides |
US7700549B2 (en) | 1997-01-07 | 2010-04-20 | Amylin Pharmaceuticals, Inc. | Exendin agonist analogs to treat diabetes |
US6956026B2 (en) | 1997-01-07 | 2005-10-18 | Amylin Pharmaceuticals, Inc. | Use of exendins for the reduction of food intake |
US7419952B2 (en) | 1997-01-07 | 2008-09-02 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof to treat diabetes |
US7138375B2 (en) | 1997-01-07 | 2006-11-21 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for lowering plasma lipid |
US6989366B2 (en) | 1997-01-07 | 2006-01-24 | Amylin Pharmaceuticals, Inc. | Exendins, exendin agonists, and methods for their use |
US7115569B2 (en) | 1997-01-07 | 2006-10-03 | Amylin Pharmaceuticals, Inc. | Exendins, exendin agonists, and methods for their use |
US7858740B2 (en) | 1997-08-08 | 2010-12-28 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US8263550B2 (en) | 1997-08-08 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US7223725B1 (en) | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US7696161B2 (en) | 1997-11-14 | 2010-04-13 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US6555521B2 (en) | 1997-12-16 | 2003-04-29 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
USRE41133E1 (en) | 1997-12-16 | 2010-02-16 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
US6998387B1 (en) | 1998-03-19 | 2006-02-14 | Amylin Pharmaceuticals, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
WO1999047161A1 (en) * | 1998-03-19 | 1999-09-23 | Bionebraska, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
EP1666054A1 (en) * | 1998-08-28 | 2006-06-07 | Eli Lilly & Company | Method for administering insulinotropic peptides |
US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
EP0997151A3 (en) * | 1998-08-28 | 2000-09-20 | Eli Lilly And Company | Method for administering insulinotropic peptides |
EP0997151A2 (en) * | 1998-08-28 | 2000-05-03 | Eli Lilly And Company | Method for administering insulinotropic peptides |
US7368427B1 (en) | 1998-12-07 | 2008-05-06 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | GLP-1 analogues |
SG125915A1 (en) * | 1998-12-07 | 2006-10-30 | Sod Conseils Rech Applic | Analogues of glp-1 |
WO2000034331A2 (en) * | 1998-12-07 | 2000-06-15 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Analogues of glp-1 |
AU762012B2 (en) * | 1998-12-07 | 2003-06-19 | Ipsen Pharma S.A.S. | Analogues of GLP-1 |
US7977455B2 (en) | 1998-12-07 | 2011-07-12 | Ipsen Pharma, S.A.S. | Analogues of GLP-1 |
WO2000034331A3 (en) * | 1998-12-07 | 2000-11-16 | Sod Conseils Rech Applic | Analogues of glp-1 |
US6903186B1 (en) | 1998-12-07 | 2005-06-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S | Analogues of GLP-1 |
US7235628B2 (en) | 1998-12-07 | 2007-06-26 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Analogues of GLP-1 |
US8138305B2 (en) | 1998-12-07 | 2012-03-20 | Ipsen Pharma S.A.S. | Analogues of GLP-1 |
EP2322545A1 (en) * | 1998-12-07 | 2011-05-18 | Ipsen Pharma | Analogues of GLP-1 |
NO319128B1 (en) * | 1998-12-07 | 2005-06-20 | Soc De Conseils De Recherches Et Dapplications Scientifiques Scras | Analogs of GLP-1, their use and pharmaceutical compositions. |
US7268213B2 (en) | 1998-12-07 | 2007-09-11 | Societe De Conselis De Recherches Et D'applications Scientitiques, S.A.S. | Analogues of GLP-1 |
EP1359159A3 (en) * | 1998-12-07 | 2004-07-21 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Analogues of GLP-1 |
EP2112161A2 (en) | 1999-07-12 | 2009-10-28 | Zealand Pharma A/S | Peptides that lower blood glucose levels |
USRE45313E1 (en) | 1999-07-12 | 2014-12-30 | Zealand Pharma A/S | Exendin variant peptides |
WO2001087322A2 (en) * | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
WO2001087322A3 (en) * | 2000-05-17 | 2002-07-18 | Bionebraska Inc | Peptide pharmaceutical formulations |
AU785444B2 (en) * | 2000-05-19 | 2007-06-14 | Jefferson Pharmaceuticals, Llc | Peptide pharmaceutical formulations |
EA008837B1 (en) * | 2000-06-16 | 2007-08-31 | Эли Лилли Энд Компани | Glucagon-like peptide-1 analogs and use thereof |
WO2001098331A2 (en) * | 2000-06-16 | 2001-12-27 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
US7498308B2 (en) | 2000-06-16 | 2009-03-03 | Eli Lilly And Company | Method of treating a subject suffering stroke comprising administering Glucagon-like peptide-1 analogs |
EP1695983A2 (en) * | 2000-06-16 | 2006-08-30 | Eli Lilly & Company | Glucagon-like peptide-1 analogs |
US7084243B2 (en) | 2000-06-16 | 2006-08-01 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
CZ304002B6 (en) * | 2000-06-16 | 2013-08-14 | Eli Lilly And Company | Glucagon-like peptide-1 |
HRP20020996B1 (en) * | 2000-06-16 | 2011-09-30 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
WO2001098331A3 (en) * | 2000-06-16 | 2003-01-03 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
EP1695983A3 (en) * | 2000-06-16 | 2007-02-21 | Eli Lilly & Company | Glucagon-like peptide-1 analogs |
EP2062593A2 (en) | 2000-12-01 | 2009-05-27 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive peptide |
US7101843B2 (en) * | 2001-08-23 | 2006-09-05 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
EP2343082A1 (en) * | 2001-09-07 | 2011-07-13 | Imperial Innovations Limited | Oxyntomodulin for preventing or treating excess weight |
US7238660B2 (en) | 2001-12-21 | 2007-07-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9296809B2 (en) | 2001-12-21 | 2016-03-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7977306B2 (en) | 2001-12-21 | 2011-07-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8071539B2 (en) | 2001-12-21 | 2011-12-06 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8993517B2 (en) | 2001-12-21 | 2015-03-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7799759B2 (en) | 2001-12-21 | 2010-09-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7847079B2 (en) | 2001-12-21 | 2010-12-07 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9221896B2 (en) | 2001-12-21 | 2015-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8252739B2 (en) | 2001-12-21 | 2012-08-28 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8513189B2 (en) | 2001-12-21 | 2013-08-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2409569A2 (en) | 2002-02-20 | 2012-01-25 | Emisphere Technologies, Inc. | Method for administering GLP-1 molecules |
US7939494B2 (en) | 2002-02-20 | 2011-05-10 | Emisphere Technologies, Inc. | Method for administering GLP-1 molecules |
US8492330B2 (en) | 2002-02-20 | 2013-07-23 | Emisphere Technologies, Inc. | Formulation comprising GLP-1 |
US7544657B2 (en) | 2002-10-02 | 2009-06-09 | Zealand Pharma A/S | Stabilized Exendin-4 compounds |
EP2368909A1 (en) | 2003-06-12 | 2011-09-28 | Eli Lilly and Company | GLP-1 analog fusion proteins |
US9486504B2 (en) | 2003-12-09 | 2016-11-08 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
US7521527B2 (en) | 2003-12-16 | 2009-04-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | GLP-1 pharmaceutical compositions |
US7897566B2 (en) | 2003-12-16 | 2011-03-01 | Ipsen Pharma S.A.S. | Analogues of GLP-1 |
US8785381B2 (en) | 2003-12-19 | 2014-07-22 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
US7538185B2 (en) | 2004-01-08 | 2009-05-26 | Theratechnologies Inc. | Glucagon-like peptide-1 analogs with long duration of action |
EP1709071A1 (en) * | 2004-01-08 | 2006-10-11 | Theratechnologies Inc. | Glucagon-like peptide-1 analogs with long duration of action |
JP2007537149A (en) * | 2004-01-08 | 2007-12-20 | セラテクノロジーズ インコーポレイテッド | Long acting glucagon-like peptide-1 analogues |
EP1709071A4 (en) * | 2004-01-08 | 2007-05-30 | Theratechnologies Inc | Glucagon-like peptide-1 analogs with long duration of action |
EP2316446A1 (en) * | 2004-06-11 | 2011-05-04 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
US8410047B2 (en) | 2004-06-11 | 2013-04-02 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
US8853157B2 (en) | 2004-06-11 | 2014-10-07 | Novo Nordisk A/S | Methods of treating steroid-induced obesity using GLP-1 agonists |
WO2005120492A1 (en) * | 2004-06-11 | 2005-12-22 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
US8183340B2 (en) | 2005-05-13 | 2012-05-22 | Eli Lilly And Company | GLP-1 pegylated compounds |
EP2441460A1 (en) | 2005-06-30 | 2012-04-18 | Ipsen Pharma | GLP-1 pharmaceutical compositions |
US8338368B2 (en) | 2005-11-07 | 2012-12-25 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US9018164B2 (en) | 2005-11-07 | 2015-04-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
EP2015769A2 (en) * | 2006-04-13 | 2009-01-21 | Societe de Conseils de Recherches et d'Applications Scientifique | Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof |
EP2015769A4 (en) * | 2006-04-13 | 2013-12-25 | Ipsen Pharma | Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof |
US8669228B2 (en) | 2007-01-05 | 2014-03-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
US8900593B2 (en) | 2007-02-15 | 2014-12-02 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9447162B2 (en) | 2007-02-15 | 2016-09-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
WO2009020802A2 (en) * | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
US8557769B2 (en) | 2007-08-03 | 2013-10-15 | Eli Lilly And Company | Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose |
WO2009020802A3 (en) * | 2007-08-03 | 2009-10-29 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
US8981047B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Glucagon antagonists |
US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
US8969294B2 (en) | 2008-06-17 | 2015-03-03 | Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.R.L. | Glucagon/GLP-1 receptor co-agonists |
US8546327B2 (en) | 2008-06-17 | 2013-10-01 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
WO2009153960A1 (en) | 2008-06-17 | 2009-12-23 | 大塚化学株式会社 | Glycosylated glp-1 peptide |
US8450270B2 (en) | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
US10117909B2 (en) | 2008-10-17 | 2018-11-06 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1 agonist |
US9526764B2 (en) | 2008-10-17 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1-agonist |
US8969288B2 (en) | 2008-12-19 | 2015-03-03 | Indiana University Research And Technology Corporation | Amide based glucagon and superfamily peptide prodrugs |
EP2216042A1 (en) | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP-1 analogues pharmaceutical compositions |
WO2010089672A1 (en) | 2009-02-09 | 2010-08-12 | Ipsen Pharma S.A.S. | Glp-1 analogues pharmaceutical compositions |
US8614185B2 (en) | 2009-05-04 | 2013-12-24 | Centocor Ortho Biotech Inc. | Fusion proteins of alpha-MSH derivatives and Fc |
WO2010129248A1 (en) | 2009-05-06 | 2010-11-11 | Centocor Ortho Biotech Inc. | Melanocortin receptor binding conjugates |
US9790263B2 (en) | 2009-06-16 | 2017-10-17 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
WO2011052523A1 (en) | 2009-10-30 | 2011-05-05 | 大塚化学株式会社 | Glycosylated form of antigenic glp-1 analogue |
US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
US10029011B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
US10028910B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
EP2754449A1 (en) * | 2010-01-21 | 2014-07-16 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
EP3357503A1 (en) * | 2010-01-21 | 2018-08-08 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
EP3216459A1 (en) * | 2010-01-21 | 2017-09-13 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
AU2016244202B2 (en) * | 2010-01-21 | 2018-03-01 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
WO2011089203A1 (en) * | 2010-01-21 | 2011-07-28 | Sanofi-Aventis | Pharmaceutical composition for treating a metabolic syndrome |
EP2359843A1 (en) * | 2010-01-21 | 2011-08-24 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
EP2460527A1 (en) * | 2010-01-21 | 2012-06-06 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
EP3607964A1 (en) * | 2010-01-21 | 2020-02-12 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
US9487571B2 (en) | 2010-01-27 | 2016-11-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
US9089538B2 (en) | 2010-04-27 | 2015-07-28 | Zealand Pharma A/S | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use |
US9649362B2 (en) | 2010-04-27 | 2017-05-16 | Zealand Pharma A/S | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use |
US10406207B2 (en) | 2010-04-27 | 2019-09-10 | Zealand Pharma A/S | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use |
US9783592B2 (en) | 2010-05-13 | 2017-10-10 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
US8778872B2 (en) | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
US9981013B2 (en) | 2010-08-30 | 2018-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US9249206B2 (en) | 2010-12-22 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US10730923B2 (en) | 2011-06-22 | 2020-08-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9758562B2 (en) | 2011-06-22 | 2017-09-12 | Indiana University and Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US10174093B2 (en) | 2011-06-22 | 2019-01-08 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9309301B2 (en) | 2011-06-22 | 2016-04-12 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9408893B2 (en) | 2011-08-29 | 2016-08-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
US9987332B2 (en) | 2011-09-01 | 2018-06-05 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
US9364519B2 (en) | 2011-09-01 | 2016-06-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
WO2013049234A2 (en) | 2011-09-26 | 2013-04-04 | Novartis Ag | Dual function proteins for treating metabolic disorders |
US9861706B2 (en) | 2011-11-03 | 2018-01-09 | Zealand Pharma A/S | GLP-1 receptor agonist peptide gastrin conjugates |
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
WO2013093720A2 (en) | 2011-12-22 | 2013-06-27 | Pfizer Inc. | Anti-diabetic compounds |
US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
WO2014010586A1 (en) | 2012-07-10 | 2014-01-16 | 武田薬品工業株式会社 | Pharmaceutical preparation for injection |
US11795204B2 (en) | 2012-07-23 | 2023-10-24 | Zealand Pharma A/S | Glucagon analogues |
US9975939B2 (en) | 2012-09-17 | 2018-05-22 | Zealand Pharma A/S | Glucagon analogues |
US10253081B2 (en) | 2012-09-17 | 2019-04-09 | Zealand Pharma A/S | Glucagon analogues |
US9839675B2 (en) | 2013-02-04 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US9200051B2 (en) | 2013-05-28 | 2015-12-01 | Takeda Pharmaceutical Company Limited | Peptide compound |
US10087229B2 (en) | 2013-05-28 | 2018-10-02 | Takeda Pharmaceutical Company Limited | Peptide compound |
WO2015021871A1 (en) | 2013-08-13 | 2015-02-19 | 杭州鸿运华宁生物医药工程有限公司 | Antibody specifically binding to glp-1r and fusion protein thereof with glp-1 |
KR20160055789A (en) | 2013-08-13 | 2016-05-18 | 지맥스 바이오팜 엘엘씨 | Antibody specifically binding to glp-1r and fusion protein thereof with glp-1 |
US10457714B2 (en) | 2013-10-17 | 2019-10-29 | Zealand Pharma A/S | Acylated glucagon analogues |
US11884713B2 (en) | 2013-10-17 | 2024-01-30 | Zealand Pharma A/S | Acylated glucagon analogues |
US11091528B2 (en) | 2013-10-17 | 2021-08-17 | Zealand Pharma A/S | Acylated glucagon analogues |
US11034747B2 (en) | 2013-10-17 | 2021-06-15 | Zealand Pharma A/S | Glucagon analogues and methods of use |
WO2015057908A1 (en) | 2013-10-18 | 2015-04-23 | Novartis Ag | Methods of treating diabetes and related disorders |
US10131702B2 (en) | 2013-11-06 | 2018-11-20 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
US11008375B2 (en) | 2013-11-06 | 2021-05-18 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
US11111285B2 (en) | 2013-11-06 | 2021-09-07 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
US9895423B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US10610595B2 (en) | 2014-01-09 | 2020-04-07 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US9963496B2 (en) | 2014-02-18 | 2018-05-08 | Novo Nordisk A/S | Stable glucagon analogues and use for treatment of hypoglycaemia |
WO2015124612A1 (en) * | 2014-02-18 | 2015-08-27 | Novo Nordisk A/S | Stable glucagon analogues and use for treatment of hypoglycaemia |
US10413593B2 (en) | 2014-10-24 | 2019-09-17 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and GLP-1 receptors |
US10253078B2 (en) | 2014-10-29 | 2019-04-09 | Zealand Pharma A/S | GIP agonist compounds and methods |
US11814417B2 (en) | 2014-10-29 | 2023-11-14 | Zealand Pharma A/S | GIP agonist compounds and methods |
US11001619B2 (en) | 2014-10-29 | 2021-05-11 | Zealand Pharma A/S | GIP agonist compounds and methods |
US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
US10538569B2 (en) | 2014-12-31 | 2020-01-21 | Genexine, Inc. | Fusion polypeptide containing GLP and immunoglobulin hybrid Fc and use thereof |
US10434147B2 (en) | 2015-03-13 | 2019-10-08 | Sanofi-Aventis Deutschland Gmbh | Treatment type 2 diabetes mellitus patients |
US10159713B2 (en) | 2015-03-18 | 2018-12-25 | Sanofi-Aventis Deutschland Gmbh | Treatment of type 2 diabetes mellitus patients |
US11274136B2 (en) | 2015-04-16 | 2022-03-15 | Zealand Pharma A/S | Acylated glucagon analogue |
US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
US10501516B2 (en) | 2016-05-24 | 2019-12-10 | Takeda Pharmaceutical Company Limited | Peptide compound |
US10905745B2 (en) | 2016-12-09 | 2021-02-02 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
US11395847B2 (en) | 2016-12-09 | 2022-07-26 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
US11752198B2 (en) | 2017-08-24 | 2023-09-12 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
US11752173B2 (en) | 2017-12-19 | 2023-09-12 | Beijing Jiyuan Biological Technology Co., Ltd. | FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease |
JP2021515026A (en) * | 2018-03-09 | 2021-06-17 | 上海仁会生物制▲やく▼股▲ふん▼有限公司Shanghai Benemae Pharmaceutical Corporation | GLP-1 composition for the treatment of obesity and weight management |
WO2019170153A1 (en) | 2018-03-09 | 2019-09-12 | Shanghai Benemae Pharmaceutical Corporation | GLP-1 Composition for Treating Obesity and Weight Management |
WO2019179424A1 (en) | 2018-03-20 | 2019-09-26 | 鸿运华宁(杭州)生物医药有限公司 | Gipr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof |
WO2021052349A1 (en) | 2019-09-18 | 2021-03-25 | 鸿运华宁(杭州)生物医药有限公司 | Gipr antibody and fusion protein between same and glp-1, and pharmaceutical composition and application thereof |
US11318191B2 (en) | 2020-02-18 | 2022-05-03 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
IL129852A (en) | 2007-10-31 |
PT946191E (en) | 2003-06-30 |
ES2194224T3 (en) | 2003-11-16 |
EP0946191A1 (en) | 1999-10-06 |
NO992557D0 (en) | 1999-05-27 |
NO992557L (en) | 1999-06-15 |
HUP0003314A3 (en) | 2001-12-28 |
CN1242707A (en) | 2000-01-26 |
US6583111B1 (en) | 2003-06-24 |
UA65549C2 (en) | 2004-04-15 |
US20070173452A1 (en) | 2007-07-26 |
AU734042B2 (en) | 2001-05-31 |
IL129852A0 (en) | 2000-02-29 |
HK1024874A1 (en) | 2000-10-27 |
HUP0003314A2 (en) | 2001-02-28 |
CA2271169A1 (en) | 1998-05-14 |
US6191102B1 (en) | 2001-02-20 |
US7211557B2 (en) | 2007-05-01 |
DK0946191T3 (en) | 2003-07-14 |
CA2271169C (en) | 2012-09-04 |
AU5245798A (en) | 1998-05-29 |
YU24199A (en) | 2002-12-10 |
DE69719798D1 (en) | 2003-04-17 |
ATE234112T1 (en) | 2003-03-15 |
NZ335995A (en) | 2001-02-23 |
MY129220A (en) | 2007-03-30 |
US20040018975A1 (en) | 2004-01-29 |
DE69719798T2 (en) | 2004-02-12 |
EP0946191B1 (en) | 2003-03-12 |
CN1268391C (en) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6191102B1 (en) | Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity | |
AU766375B2 (en) | Use of GLP-1 or analogs in treatment of stroke | |
EP0964873B1 (en) | Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery | |
US6747006B2 (en) | Use of GLP-1 or analogs in treatment of myocardial infarction | |
EP1227151A1 (en) | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use | |
EP1306092A2 (en) | Use of GLP-1 and analogs administered peripherally, in regulation of obesity | |
US20060160740A1 (en) | Use of GLP-1 or analogs in treatment of stroke | |
AU2003270960B2 (en) | Use of GLP-1 or Analogs in Treatment of Stroke | |
CZ165199A3 (en) | Medicament for reducing body weight or obesity | |
MXPA99004662A (en) | Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity | |
EP1652531A1 (en) | Use of GLP-1 or Analogues in Treatment of Stroke | |
PL191627B1 (en) | Application of peripherally administered glp-1 analoques and derivatives in treating obesity | |
MXPA01003008A (en) | Use of glp-1 or analogs in treatment of stroke | |
EP1566180A2 (en) | Use of GLP-1 or Analogs in Treatment of Myocardial Infarction | |
MXPA99001873A (en) | Use of glp-1 or analogs in treatment of myocardial infarction | |
MXPA99001871A (en) | Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-241/99 Country of ref document: YU Ref document number: 97181232.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2271169 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-1651 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/004662 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 335995 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997947357 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 52457/98 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997947357 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-1651 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997947357 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 52457/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997947357 Country of ref document: EP |